IL-33–Stimulated Murine Mast Cells Polarize Alternatively Activated Macrophages, Which Suppress T Cells That Mediate Experimental Autoimmune Encephalomyelitis
- 1 October 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 205 (7) , 1909-1919
Abstract
IL-33 is known to promote type 2 immune responses through ST2, a component of the IL-33R complex, expressed primarily on mast cells, Th2 cells, group 2 innate lymphoid cells and regulatory T cells, and to a lesser extent, on NK cells and Th1 cells. Consistent with previous studies, we found that IL-33 polarized alternatively activated macrophages (AAMΦ) in vivo. However, in vitro stimulation of murine bone marrow–derived or peritoneal macrophages with IL-33 failed to promote arginase activity or expression of YM-1 or Retnla, markers of AAMΦ. Furthermore, macrophages have low/no basal expression of ST2. This suggested that alternative activation of macrophages may involve an IL-33–responsive third-party cell. Because mast cells have the highest expression of ST2 relative to other leukocytes, we focused on this cell type. Coculture experiments showed that IL-33–stimulated mast cells polarized AAMΦ through production of soluble factors. IL-33–stimulated mast cells produced a range of cytokines, including IL-6 and IL-13. Mast cell–derived IL-13 was required for induction of AAMΦ, whereas mast cell–derived IL-6 enhanced macrophage responsiveness to IL-13 via upregulation of the IL-4Rα receptor. Furthermore, we found that AAMΦ polarized by IL-33–stimulated mast cells could suppress proliferation and IL-17 and IFN-γ production by T cells. Finally, we show that AAMΦ polarized by IL-33–stimulated mast cells attenuated the encephalitogenic function of T cells in the experimental autoimmune encephalomyelitis model. Our findings reveal that IL-33 can promote immunosuppressive responses by polarizing AAMΦ via mast cell–derived IL-6 and IL-13.Keywords
This publication has 50 references indexed in Scilit:
- Decoding asthma: Translating genetic variation in IL33 and IL1RL1 into disease pathophysiologyJournal of Allergy and Clinical Immunology, 2013
- NCBI GEO: archive for functional genomics data sets—updateNucleic Acids Research, 2012
- Contribution of IL-33–activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected miceProceedings of the National Academy of Sciences, 2012
- IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin GProceedings of the National Academy of Sciences, 2012
- Paracrine IL-33 Stimulation Enhances Lipopolysaccharide-Mediated Macrophage ActivationPLOS ONE, 2011
- Interleukin-33 Is Biologically Active Independently of Caspase-1 CleavageJournal of Biological Chemistry, 2009
- Arginase-1–Expressing Macrophages Suppress Th2 Cytokine–Driven Inflammation and FibrosisPLOS Pathogens, 2009
- The IL-1-Like Cytokine IL-33 Is Constitutively Expressed in the Nucleus of Endothelial Cells and Epithelial Cells In Vivo: A Novel ‘Alarmin’?PLOS ONE, 2008
- IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cellsProceedings of the National Academy of Sciences, 2007
- IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factorin vivoProceedings of the National Academy of Sciences, 2007